Skip to main content
Medical information Clinical review pending

Genetic Testing

TERT Gene Leukemia Acute Myeloid Form Susceptible Due to TERT Germline Mutation Genetic Test

This genetic test identifies mutations in the TERT gene that may increase susceptibility to acute myeloid leukemia (AML). It uses Next Generation Sequencing (NGS) to analyze DNA.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or other tissue sample as specified by the laboratory. Confirm specific requirements before collection.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required for a blood draw. Follow any instructions provided by the laboratory regarding fasting or medication adjustments.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the TERT Gene Leukemia Acute Myeloid Form Susceptible Due to TERT Germline Mutation Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with a family history of leukemia or related blood disorders.
  • ✓Patients presenting with symptoms suggestive of leukemia.
  • ✓Individuals diagnosed with AML seeking further genetic information.
  • ✓Risk assessment for individuals with specific genetic backgrounds.
02

In plain language

What this test helps you understand

Identifies TERT gene mutations associated with increased susceptibility to acute myeloid leukemia (AML). Results may inform risk assessment, monitoring, and potentially treatment strategies. Genetic counseling is recommended to interpret results.
The TERT Gene Leukemia Acute Myeloid Form Susceptible Due to TERT Germline Mutation NGS Genetic DNA Test is an advanced diagnostic tool used to identify specific genetic mutations associated with an increased risk of developing acute myeloid leukemia (AML). This test utilizes Next Generation Sequencing (NGS) technology to analyze the TERT gene, which is involved in cellular aging and has been linked to cancer development. Understanding the presence of these mutations can provide valuable information for managing risk and potentially influencing treatment approaches.

This genetic test specifically looks for mutations within the TERT gene that may predispose individuals to AML. The analysis is performed on DNA extracted from a blood sample or other suitable tissue. The results can offer insights into the genetic factors contributing to the risk of developing this type of leukemia.

Individuals who might consider this test include those with a family history of leukemia or related blood disorders, patients presenting with symptoms suggestive of leukemia (such as persistent fatigue, frequent infections, or unexplained bruising), or individuals already diagnosed with AML who wish to understand potential genetic factors influencing their condition.

Taking this test can offer several benefits, including identifying a genetic predisposition to AML, which may allow for closer monitoring or preventative measures. It can also inform personalized treatment strategies based on genetic findings and aid in genetic counseling for the patient and their family. Understanding these genetic factors can contribute to better disease management.

Results will indicate whether specific mutations in the TERT gene were detected. It is highly recommended to discuss the results with a healthcare provider or genetic counselor to understand their implications for health, treatment, and family members. Confirm with the laboratory before booking for specific turnaround time details.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required for a blood draw. Follow any instructions provided by the laboratory regarding fasting or medication adjustments.
SampleBlood sample (EDTA tube) or other tissue sample as specified by the laboratory. Confirm specific requirements before collection.
MethodologyNext Generation Sequencing (NGS) analysis of DNA.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects specific mutations in the TERT gene. It does not rule out other genetic or environmental factors contributing to AML risk. A negative result does not guarantee an individual will not develop AML. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The TERT gene provides instructions for making an enzyme called telomerase reverse transcriptase. This enzyme is important for maintaining the ends of chromosomes (telomeres) during cell division. Mutations in this gene have been linked to an increased risk of certain cancers, including AML.
This test may be considered for individuals with a family history of leukemia, those experiencing symptoms suggestive of leukemia, or individuals diagnosed with AML seeking to understand genetic risk factors. Discuss with your doctor if this test is appropriate for you.
The results will indicate whether specific mutations associated with AML risk were found in the TERT gene. A positive result suggests an increased susceptibility. It is crucial to discuss the results with a healthcare provider or genetic counselor for proper interpretation.
No, this test identifies genetic susceptibility factors. It is not a diagnostic test for AML itself. Diagnosis requires clinical evaluation, blood tests, and potentially bone marrow examination.
It is recommended to have a follow-up appointment with your doctor or a genetic counselor to discuss the results, their implications for your health and family, and any potential next steps.
Typically, a blood sample is collected. Confirm the specific sample requirements and collection procedures with the laboratory before your appointment.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp